Shilpa Buch, Ph.D.
ProfessorShilpa Buch

Durham Research Center, Room 8011
985880 Nebraska Medical Center
Omaha, NE 68198-5880

Phone: 402-559-3165

E-mail: Shilpa Buch

Keywords: drugs of abuse, neuroAIDS, immunology


Professional Summary
Research Interests
Representative Publications
Biographical Information

Visit Dr. Buch's Laboratory
Nebraska Center for Substance Abuse


In the news:

InterCOM | July/August 2017
Research highlights

UNMC Today | November 21, 2016
UNMC scientists honored for neurovirology impact

KETV.com I July 6, 2016
Lincoln businessman takes issues with Whiteclay to Nebraska Liquor Control Commission

Journal Star I July 5, 2016
 Alcohol problems in Whiteclay consume county's budget

Live Well Nebraska I June 26, 2016
From documentaries to the Capitol to UNMC, focus sharpens on alcohol problem in Whiteclay

UNMC For the Record I June 24, 2016
Dr. Buch completes ELAM Program for Women

KETV.com I June 13, 2016
Inside the troubles of Whiteclay

2016 Science Festival Highlights I June 1, 2016

UNMC Today, February 11, 2016
Shilpa Buch, Ph.D., is UNMC's 10th Scientist Laureate

UNMC Today, February 9, 2016
Under the Microscope:  UNMC Scientist Laureate Shilpa Buch, Ph.D.

UNMC Today, December 14, 2015
Shilpa Buch, Ph.D., is UNMC's 10th Scientist Laureate

UNMC Today, November 4, 2015
Substance abuse research center holds symposium
Inaugural Event program

Archive News

You TubeDr. Buch in her own words.


Professional summary:

Infection with HIV-1 is frequently complicated in its late stages by a neurological syndrome, HIV-associated dementia (HAD), clinically characterized by abnormalities in cognition, motor performance, and behavior. While the exact mechanism(s) by which HIV-1 causes CNS pathology are not completely understood, increasing evidence suggests that a state of immune activation associated with increased levels of pro-inflammatory cytokines is an important factor contributing to neuronal damage.

These pro-inflammatory cytokines can, in turn, synergize with the viral proteins released from HIV-infected cells to generate neurotoxins resulting in progressive neuronal damage associated with HAD. Interestingly, it is becoming increasingly clear that although the initial trigger of HAD is the virus, the severity of the disease correlates more closely with the presence of activated cells than with the presence and amount of HIV-infected cells in the brain.

Despite the preponderance of HIV for macrophages and CD4+T cells, virtually all the resident cells of the CNS are players contributing to the disease process.

To date, several aspects of HAD pathogenesis remain to be dissected. Using a multipronged approach comprising of in vitro cell systems, complemented with rodent models and the higher more relevant macaque model of SIV pathogenesis, and archival human tissue, our research aims to dissect the mechanism(s) of CNS pathology triggered by the host-virus interplay. Specifically, we are interested in the role of each CNS cell type as it contributes cumulatively to the disease process.

Research Interests:

  1. The Chemokine Connection: CXCL10 or interferon γ-inducible peptide has been detected in the CSF of individuals with HIV-1 infection and is closely associated with the progression of HIV-1 related CNS infection and neuropsychiatric impairment. Using the macaque model of HIV neuropathogenesis, we have identified the role of this chemokine as a potent neurotoxin that is linked to virus-associated encephalitis. Specifically, we have demonstrated the signaling pathways by which viral proteins cause regulated induction of this chemokine, thereby resulting in apoptotic cell death. Additionally, papers from our laboratory suggest that in astrocytes, the interplay of viral proteins with the inflammatory mediators (IFN-γ/TNF-α) can lead to synergistic induction of this neurotoxin, via the oxidative stress pathway.
  2. Endogenous Neuroprotective Pathways: CNS homeostasis is a fine balance of neuroprotective and neurotoxic pathways. However, this can be a double-edged sword, as a well-intentioned protective response, if extended for a long time, can go awry. We have been interested in exploring endogenous cellular pathways that can augment neuronal survival. In our recent findings we report unconventional role for the HAD-associated chemokine, MCP-1 - that of neuroprotection against virus toxicity. Similarly, we have also reported the paradoxical role of platelet-derived growth factor as a neuroprotective factor against HIV toxicity. These are very intriguing findings as they lend credence to the existence of selective "anatomical niches" in the CNS. Our ultimate goal is to examine the roles of these host mediators as therapeutic agents that can mitigate CNS inflammation and impaired synaptic transmission in vivo.
  3. Drugs of Abuse and HIV Co-operativity: Injection drug abuse is a major cause of the spread of HIV/AIDS. Heroin, morphine and other opioids not only promote HIV infection and the progression of AIDS, but also appear to intrinsically exacerbate the frequency and severity of HIV encephalitis (HIVE) in the CNS. We are actively pursuing how cocaine synergizes with HIV/HIV proteins to exacerbate disease pathogenesis. Our findings imply that that cocaine can act at multiple steps within the CNS to promote neuronal toxicity, specifically impacting the blood brain barrier breach and enhancing virus replication in macrophages. Another highly relevant area of research in our lab is aimed at examining the effect of morphine on progression of HIVE in SIV-infected macaques, which are an excellent analog of HIV encephalopathy.
  4. HIV, aging and NeuroAIDS: The now chronic nature of HIV has led to a major advancement in AIDS care. While HIV infected individuals are living longer, damaging effects of HIV persist in the brain and may interact with other neurodegenerative disorders. Dr. Buch, along with dR. Howard Fox, leads the Chronic HIV infection and Aging in NeuroAIDS Center (CHAIN). The Center is supported by NIH, NIMH P30 MH062261.  The goal of the CHAIN Center is to provide the necessary leadership and backbone of support to continue the outstanding research on HIV/AIDS, aging and the central nervous system ongoing at the University of Nebraska Medical Center and throughout the nation. Experts in a number of fields direct the Cell-Tissue-AnimalImagingOmics, and Therapeutics cores, along with the Administrative and Developmental cores. Visit the CHAIN Center web site for more information.

Long-range Goals:

The long term goal of our group is to identify novel therapeutic strategies that may enhance neuronal function and survival in NeuroAIDS, with possible implications in other neurodegenerative diseases.

top of page


Representative Publications

  1. Niu F, Yao H, Zhang W, Sutliff RL, Buch S. (2014) Tat 101-mediated enhancement of brain pericyte migration involves platelet-derived growth factor subunit B homodimer: implications for human immunodeficiency virus-associated neurocognitive disorders. J Neurosci 34(35):11812-25. PMID 25164676
  2. Yao H, Ma R, Yang L, Hu G, Chen X, Duan M, Kook Y, Niu F, Liao K, Fu M, Hu G, Kolattukudy P, Buch S. (2014) MiR-9 promotes microglial activation by targeting MCPIP1. Nat Commun. 5:4386. PMID 25019481
  3. Yao H, Bethel-Brown C, Niu F, Yang L, Peng F, Buch S. (2014) Yin and Yang of PDGF-mediated signaling pathway in the context of HIV infection and drug abuse. J Neuroimmune Pharmacol. 9(2):161-7. PMID 23784143
  4. Yao H, Duan M, Yang L, Buch S. (2012) Platelet-Derived Growth Factor-BB Restores Human Immunodeficiency Virus Tat-Cocaine-Mediated Impairment of Neurogenesis: Role of TRPC1 Channels.   J. Neurosci. 32(29):9835-47. PMID 22815499
  5. Buch, S, Yao, H, Guo M, Mori T, Seth P, Wang J, Su TP. (2012) Cocaine and HIV-1 Interplay in CNS: Cellular and Molecular Mechanisms. Curr HIV Res May 11. PMID 22591366
  6. Yao, H and Buch S. Rodent models of HAND and drug abuse: exongenous administration of viral protein(s) and cocaine. (2012) J. Neuroimmune Pharmacol 7(2):341-51. PMID 22447295
  7. Yao H, Duan M, Hu G, Buch S. (2011) Platelet-derived growth factor B chain is a novel target gene of cocaine-mediated Notch1 signaling: implications for HIV-associated neurological disorders) J Neurosci 31(35):12449-54. PMID 21880906
  8. Buch S, Yao H, Guo M, Mori T, Su TP, Wang J. (2011)  Cocaine and HIV-1 interplay: molecular mechanisms of action and addition. J. Neuroimmune Pharmacol 6(4):503-15. PMID 21766222
  9. Wen H, Lu Y, Yao H, Buch S. (2011) Morphine induces expression of platelet-derived growth factor in human brain microvascular endothelial cells: implication for vascular permeability. PLoS One 6(6):e21707. PMID 21738771
  10. Yao H, Kim K, Duan M, Hayaski T, Guo M, Morgello S, Prat A, Wang J, Su TP, Buch S. (2011) Cocaine hijacks sigma1 receptor to initiate induction of activated leukocyte cell adhesion molecule: implication for increased monocyte adhesion and migration in the CNS.   J Neurosci 31(16):5942-55. PMID 21508219
  11. Peng F, Yao H, Bai X, Zhu X, Reiner BC, Beazely M, Funa K, Xiong H, Buch S.(2010) Platelet-derived growth factor-mediated induction of the synaptic plasticity gene Arc/Arg3.1. J Biol Chem. 285 (28):21615-24. PMID 20452974
  12.  Yao H, Bethel-Brown C, Li CZ, Buch SJ. (2010) HIV Neuropathogenesis: a Tight Rope Walk of Innate Immunity. J Neuroimmune Pharmacol. 5(4):489-495. PMID 20354805
  13. Yao H, Yang Y, Kim KJ, Bethel-Brown C, Gong N, Funa K, Gendelman HE, Su TP, Wang JQ, Buch S. (2010) Molecular mechanisms involving sigma receptor-mediated induction of MCP-1: implication for increased monocyte transmigration. Blood. 115(23):4951-62. PMID 20354174
Additional Publications in PubMed

Dr. Buch's biographical information
Visit Dr. Buch's laboratory
top of page